Ribozyme repurchases compound rights from Eli Lilly

RZYM repurchased rights from LLY to its Heptazyme (LY466700) chemically synthesized ribozyme against hepatitis C virus (HCV) (see BioCentury, March 29, 1999). Earlier this month, RZYM reported prelim...